

# Supplementary Material 1

## Robust Transfer Learning for Personalized Continuous Blood Pressure Changes Estimation: Testing during Autonomic Dysregulation Episodes of SCI Individuals

### S1. Extended Evaluation Tables (Aurora BP)

This section presents a detailed evaluation of the proposed multimodal framework for  $\Delta$ SBP prediction on the Aurora BP test set (n=93). Performance is stratified by blood pressure category, including Normal, Elevated, Hypertension Stage 1, and Hypertension Stage 2, as defined by the American Heart Association (AHA). We evaluate four input configurations: PPG only, ECG only, dual-modal PPG+ECG, and a full multimodal variant incorporating demographic features (PPG+ECG+Demo). Metrics include Root Mean Square Error (RMSE), Mean Absolute Error (MAE), and Mean Deviation (MD), each reported with their corresponding standard deviations (SD). These metrics reflect both the accuracy and consistency of the model across physiologically distinct BP categories.

Table 1: Category-wise performance of  $\Delta$ SBP prediction with RMSE, MAE, and MD (mean (std)) on Aurora BP test set (hold-out) (n = 93)

BP Group	PPG	ECG	PPG+ECG	PPG+ECG+Demo
RMSE				
Normal	13.56	16.50	13.03	12.28
Elevated	10.84	13.81	9.77	8.93
Hypertension S1	16.89	12.97	13.75	12.71
Hypertension S2	20.89	21.16	20.48	20.21
MAE $\pm$ SD (mmHg)				
Normal	9.77 $\pm$ 9.40	11.97 $\pm$ 11.35	9.52 $\pm$ 8.90	8.62 $\pm$ 8.75
Elevated	8.04 $\pm$ 7.28	9.38 $\pm$ 10.14	7.11 $\pm$ 6.71	6.65 $\pm$ 5.97
Hypertension S1	9.46 $\pm$ 9.17	11.01 $\pm$ 10.41	9.85 $\pm$ 9.59	9.30 $\pm$ 8.73
Hypertension S2	14.93 $\pm$ 15.10	24.27 $\pm$ 17.86	15.19 $\pm$ 13.74	14.80 $\pm$ 13.76
MD $\pm$ SD (mmHg)				
Normal	2.44 $\pm$ 13.34	9.43 $\pm$ 13.54	4.85 $\pm$ 12.09	3.53 $\pm$ 11.77
Elevated	-4.80 $\pm$ 9.72	6.54 $\pm$ 12.17	1.00 $\pm$ 9.72	0.10 $\pm$ 8.93
Hypertension S1	-8.39 $\pm$ 14.66	3.81 $\pm$ 12.39	-3.98 $\pm$ 13.16	-1.24 $\pm$ 12.70
Hypertension S2	-10.48 $\pm$ 18.07	3.56 $\pm$ 20.86	-1.14 $\pm$ 20.45	4.15 $\pm$ 19.86

The full multimodal configuration consistently achieved superior performance across all BP groups. It notably reduced both MAE and RMSE, especially in the 'Elevated' category, and demonstrated lower bias and variability (MD  $\pm$  SD) across hypertensive groups. These findings support the benefit of demographic fusion in enhancing the robustness and generalizability of beat-to-beat BP estimation.

## Interpretation of Category-Wise Results

Table 1 presents category-wise evaluation of  $\Delta$ SBP prediction across four input configurations. The full multimodal model (PPG+ECG+Demographics) consistently achieved the lowest RMSE and MAE in all BP groups, with particularly strong gains in the ‘Normal’ and ‘Elevated’ categories. It also yielded the smallest mean deviation (MD) values, indicating reduced prediction bias and improved calibration across clinically relevant BP ranges. Single-sensor models exhibited higher error and variability, especially in hypertensive groups, reflecting limited robustness under physiologically unstable conditions. While demographic fusion enhanced performance in stable BP profiles, its impact diminished in more variable states (e.g., Hypertension Stage 2), likely due to waveform degradation and increased signal noise. Nonetheless, the full model demonstrated consistent bias reduction and lower dispersion ( $MD \pm SD$ ), supporting its role as a reliable initialization point for transfer learning in small, high-variance datasets such as SCI. These results underscore the effectiveness of multimodal integration in improving both accuracy and generalization for beat-to-beat BP estimation.

## Visual Agreement Analysis (Bland–Altman):






Figure 1. Bland Altman plot for various BP subgroups and phases

To complement the numerical metrics Figure 1 shows the Bland–Altman plots stratified by BP categories. Subgroup-specific analyses reveal important differences. In the Normal (1a) and Elevated (1b) BP groups, the SD are relatively narrower, and residuals appear symmetrically distributed, indicating more consistent model behavior. Conversely, the Hypertension Stage 1 (1c) and Stage 2 (1d) groups exhibit wider dispersion and increased bias, reflecting diminished reliability in more dysregulated physiological states. Measurement conditions also affect model performance. During in-clinic assessments (1e), prediction errors are centered with reduced spread, suggesting higher stability under controlled conditions. In contrast, ambulatory phases (1f) show greater variance and mild skew, likely due to posture changes, motion artifacts, and environmental noise impacting waveform quality.

Collectively, these results confirm that while the model maintains low overall bias, its reliability varies with both clinical context and BP category—highlighting the importance of stratified evaluation.

Regulatory Evaluation of ΔSBP Prediction

Table 2: Evaluation of ΔSBP prediction on the Aurora BP test set (hold-out) under standard protocols

Standard	Metric	Value
IEEE 1708a-2019	Static ME (mmHg)	−0.78
	Static SD (mmHg)	4.44
	Dynamic ME (mmHg)	−0.38
	Dynamic SD (mmHg)	14.99
	Combined ME (mmHg)	0.80
	Combined SD (mmHg)	12.75
	Combined MAD (mmHg)	9.05
ANSI/AAMI SP10	ME (mmHg)	−0.49
	SD (mmHg)	13.02
	Meets Criteria (SD ≤ 8 mmHg)	No
BHS	≤ 5 mmHg (%)	44.6%
	≤ 10 mmHg (%)	64.7%
	≤ 15 mmHg (%)	78.9%
	Grade	D

Table 2 presents the evaluation of ΔSBP prediction under IEEE 1708a-2019, AAMI, and BHS protocols. The model performed notably better under static conditions, with substantially lower variability compared to dynamic segments, reflecting the impact of motion artifacts and physiological noise in ambulatory settings. While overall bias remained low, the standard deviation exceeded the AAMI threshold, and the BHS grading corresponded to a Grade D. Although formal regulatory criteria were not met, these outcomes underscore the difficulty of beat-to-beat BP estimation in real-world scenarios and reinforce the need for state-aware evaluation strategies.